Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vogt-Koyanagi-Harada disease.

Francisco Max Damico1, Szilárd Kiss, Lucy H Young

  • 1Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.

Seminars in Ophthalmology
|November 12, 2005
PubMed
Summary

Vogt-Koyanagi-Harada disease (VKH) is a multisystem autoimmune disorder affecting pigmented tissues. Early diagnosis and aggressive immunomodulatory treatment, often with corticosteroids, lead to a good visual prognosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eye care workforce density by provider type in urban and rural counties in the United States, 2010 to 2021.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Literature Review and Institutional Imaging Analysis of Ritonavir Retinal Toxicity.

Journal of vitreoretinal diseases·2026
Same author

Sildenafil use and risk of serous retinal detachment in men with erectile dysfunction in US.

Eye (London, England)·2026
Same author

Association between PCSK9 inhibitor use and risk of age-related macular degeneration.

Eye (London, England)·2026
Same author

Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study.

Ophthalmology·2026
Same author

Immune Recovery Uveitis: A Comprehensive Review.

International ophthalmology clinics·2025

Area of Science:

  • Ophthalmology
  • Immunology
  • Genetics

Background:

  • Vogt-Koyanagi-Harada (VKH) disease is a rare autoimmune disorder impacting multiple organ systems, primarily those with pigmented tissues.
  • It affects the eyes, ears, skin, and central nervous system, typically in individuals aged 20-50, with a higher prevalence in certain ethnic groups.
  • The disease course involves distinct phases, from prodromal symptoms to uveitis, depigmentation, and potential chronic recurrence.

Purpose of the Study:

  • To provide a comprehensive overview of Vogt-Koyanagi-Harada disease.
  • To detail the clinical presentation, diagnostic criteria, and pathogenesis of VKH.
  • To outline current treatment strategies and prognostic factors.

Main Methods:

  • Review of existing literature and diagnostic criteria for VKH.
  • Analysis of the clinical course, pathogenesis, and genetic associations (e.g., HLA-DR4).
  • Summary of differential diagnoses and treatment approaches, including corticosteroids and immunosuppressants.

Main Results:

  • VKH is classified as complete, incomplete, or probable based on extraocular findings.
  • The pathogenesis involves a T-cell mediated immune response against melanocyte antigens.
  • Strong associations exist with HLA-DR4 and specific haplotypes like HLA-DRB1*0405.

Conclusions:

  • VKH diagnosis is primarily clinical, requiring differentiation from other inflammatory eye conditions.
  • Prompt and aggressive immunomodulatory treatment, initiated with corticosteroids, is crucial for favorable visual outcomes.
  • Cyclosporine and other agents may be necessary for refractory cases or to manage corticosteroid side effects.

Related Experiment Videos